Merck Group (FRA:MRK) Given a €92.00 Price Target by Goldman Sachs Analysts

Merck Group (FRA:MRK) received a €92.00 ($113.58) price objective from analysts at Goldman Sachs in a research note issued on Wednesday, March 21st. The brokerage presently has a “neutral” rating on the healthcare company’s stock. Goldman Sachs’ target price suggests a potential upside of 13.66% from the company’s current price.

Other analysts have also issued reports about the stock. Warburg Research set a €115.00 ($141.98) price objective on shares of Merck Group and gave the stock a “buy” rating in a research report on Wednesday, November 29th. Sanford C. Bernstein set a €115.00 ($141.98) target price on shares of Merck Group and gave the stock a “buy” rating in a research report on Wednesday, November 29th. UBS set a €120.00 ($148.15) target price on shares of Merck Group and gave the stock a “buy” rating in a research report on Wednesday, December 6th. Berenberg Bank set a €116.00 ($143.21) target price on shares of Merck Group and gave the stock a “buy” rating in a research report on Thursday, November 23rd. Finally, Kepler Capital Markets set a €115.00 ($141.98) target price on shares of Merck Group and gave the stock a “buy” rating in a research report on Wednesday, January 17th. Twelve research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. The company has an average rating of “Hold” and an average price target of €100.32 ($123.85).

How to Become a New Pot Stock Millionaire

Merck Group stock traded up €0.66 ($0.81) during midday trading on Wednesday, reaching €80.94 ($99.93). The stock had a trading volume of 442,289 shares. Merck Group has a 52-week low of €76.60 ($94.57) and a 52-week high of €115.00 ($141.98).

TRADEMARK VIOLATION WARNING: This article was posted by Macon Daily and is the sole property of of Macon Daily. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be viewed at https://macondaily.com/2018/04/12/goldman-sachs-analysts-give-merck-kgaa-mrk-a-92-00-price-target-updated-updated-updated.html.

Merck Group Company Profile

MERCK Kommanditgesellschaft auf Aktien, a science and technology company, operates in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat infertility, growth hormone deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, multiple sclerosis, colorectal cancer, as well as carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.

Analyst Recommendations for Merck Group (FRA:MRK)

Receive News & Ratings for Merck Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck Group and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply